5. NeurostimulationIn Pelvic Health, Martha sees early indications that market share is rebounding in the U.S. after the launch of the InterStim Micro neurostimulator, which sends electrical impulses to the sacral nerves in the lower back to improve bladder and bowel control.
“Our device is 50% smaller, it recharges far faster. And importantly, the recharger doesn’t need to be perfectly aligned for a successful charge. Additionally, Medtronic is the only company to offer physician practices, the choice of recharge and recharge free. And this is very important in the neuromodulation space,” Martha said.
Martha touted universally positive physician feedback for the InterStim Micro rechargeable product.
“In just a few weeks, we’re winning back accounts and we’re seeing cases where our competitors device is being explanted and replaced by Micro,” Martha said. “We’ve been waiting for this. Patients now have the ability to choose a smaller, better rechargeable product. Physician practices to prefer to deal with one company. And our team is enjoying taking back the share.”
In the deep brain stimulation (DBS) space, meanwhile, Medtronic won FDA approval earlier this summer for the Percept PC deep brain stimulation (DBS) system — touted as the first DBS to record brain signals while delivering therapy. Company officials see the Percept PC as the beginning of a multi-year run in DBS — with a directional lead launching next year, followed by a closed-loop DBS system.